APLLTD vs CIPLA: Stock Comparison

Alembic Pharmaceuticals Limited vs Cipla Ltd

Live data: 22 July 2026, 2:35 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Cipla Ltd shows lower leverage, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alembic Pharmaceuticals Limited and Cipla Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, APLLTD is more favourable on 8 of 13 scored metrics and CIPLA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹16,030 Cr
P/E Ratio
APLLTD has a lower P/E
24.3x vs 29.83x
P/B Ratio
APLLTD has a lower P/B
2.89x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹34.3
Dividend Yield
APLLTD has a higher dividend yield
1.42% vs 0.9%
Revenue Growth (TTM YoY)
APLLTD has faster revenue growth
4.4% vs -2.1%
EPS Growth (TTM YoY)
APLLTD has faster EPS growth
29.2% vs -54.6%
Qtr Sales Growth
APLLTD has stronger quarterly sales growth
4.41% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAPLLTDCIPLA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAPLLTDCIPLA
Live Price₹815₹1,411.5
Day Change-2.23%-1.47%
Volume43,66512.89 L
52-Week High₹1,032.7₹1,673
52-Week Low₹635.8₹1,165.7
Distance from 52W High-21.08%-15.63%

Valuation

MetricAPLLTDCIPLA
Market Cap₹16,030 Cr₹1.14 L Cr
P/E Ratio24.3x29.83x
P/B Ratio2.89x3.36x
EPS₹34.3₹48.01
Book Value₹288.7₹426.25
Dividend Yield1.42%0.9%

Growth

MetricAPLLTDCIPLA
Revenue Growth (TTM YoY)4.4%-2.1%
EPS Growth (TTM YoY)29.2%-54.6%
Qtr Sales Growth4.41%-2.8%
Qtr Profit Growth40.8%-54.6%

Profitability & Leverage

MetricAPLLTDCIPLA
ROE13.4%11.6%
ROCE12.6%15.5%
Net Margin8.98%13.96%
Operating Margin15.2%20.9%
Debt to Equity0.25x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAPLLTDCIPLA
Promoter Holding69.36% 0.13 pp9.17%
FII Holding4.18% 0.07 pp22.56% 1.37 pp
DII Holding15.94% 0.24 pp31.97% 1.25 pp
Public Holding10.01% 0.18 pp16.25% 0.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Cipla Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.